Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study. Issue 32 (August 2019)

• Record Type: Journal Article
• Authors: Kim, Yong Hoon; Her, Ae-Young; Rha, Seung-Woon; Choi, Byoung Geol; Choi, Se Yeon; Byun, Jae Kyeong; Park, Yoonjee; Kang, Dong Oh; Jang, Won Young; Kim, Woohyeun; Choi, Woong Gil; Kang, Tae Soo; Ahn, Jihun; Park, Sang-Ho; Park, Ji Young; Lee, Min-Ho; Choi, Cheol Ung; Park, Chang Gyu; Seo, Hong Seog
• Other Names: Roever. Leonardo section editor.
• Is Part Of: Medicine. Volume 98:Issue 32(2019)
• Publication Date: 2019-08
• Subjects: BioLinx -- clinical outcomes -- drug-eluting stent -- phoshorylcholine -- Polymer -- Zotarolimus; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000016767
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: There are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZES) with phosphorylcholine polymer (P)-ZES. The aim of this study was to compare the efficacy and safety of B-ZES with P-ZES in patients who underwent percutaneous coronary intervention (PCI) during a 3-year follow-up period. One thousand two hundred fifty four patients who underwent PCI with P-ZES (Endeavor [ZES-E] or Endeavor sprint [ZES-S], n = 356) or B-ZES (Endeavor resolute [ZES-R] or Resolute Integrity [ZES-I], n = 889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR), and the secondary endpoint was stent thrombosis (ST). After PSM, 2 propensity-matched (PSM) groups (275 pairs, n = 550, C-statistic = 0.730) were generated. During the 3-year follow-up period, the cumulative incidence of MACE (hazard ratio [HR], 1.525; 95% confidence interval [CI], 0.920–2.526; P = .101) and ST (HR, 1.248; 95% CI, 0.335–4.4649; P = .741) were similar between P-ZES and B-ZES after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs 3.8%, log rank P = .029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs 4.8%, log rank P = .025). In this single-center, all-comer registry, despite different polymers, P-ZES, and B-ZES showed comparable safety and efficacy during a 3-year follow-up period after PCI. Abstract : Supplemental Digital Content is available in the text